%0 Journal Article
%T Radioligands for Tropomyosin Receptor Kinase (Trk) Positron Emission Tomography Imaging
%A Alexander Thiel
%A Alexey Kostikov
%A Andrew V. Mossine
%A Anne Mahringer
%A Bj£¿rn W£¿ngler
%A Carmen W£¿ngler
%A David R. Kaplan
%A Esther Schirrmacher
%A Gert Fricker
%A Jean-Paul Soucy
%A Justin J. Bailey
%A Lena Kaiser
%A Pedro Rosa-Neto
%A Peter Bartenstein
%A Peter J. H. Scott
%A Ralf Schirrmacher
%A Simon Lindner
%A Vadim Bernard-Gauthier
%J Archive of "Pharmaceuticals".
%D 2019
%R 10.3390/ph12010007
%X The tropomyosin receptor kinases family (TrkA, TrkB, and TrkC) supports neuronal growth, survival, and differentiation during development, adult life, and aging. TrkA/B/C downregulation is a prominent hallmark of various neurological disorders including Alzheimer¡¯s disease (AD). Abnormally expressed or overexpressed full-length or oncogenic fusion TrkA/B/C proteins were shown to drive tumorigenesis in a variety of neurogenic and non-neurogenic human cancers and are currently the focus of intensive clinical research. Neurologic and oncologic studies of the spatiotemporal alterations in TrkA/B/C expression and density and the determination of target engagement of emerging antineoplastic clinical inhibitors in normal and diseased tissue are crucially needed but have remained largely unexplored due to the lack of suitable non-invasive probes. Here, we review the recent development of carbon-11- and fluorine-18-labeled positron emission tomography (PET) radioligands based on specifically designed small molecule kinase catalytic domain-binding inhibitors of TrkA/B/C. Basic developments in medicinal chemistry, radiolabeling and translational PET imaging in multiple species including humans are highlighted
%K tropomyosin receptor kinase
%K positron emission tomography
%K neurodegeneration
%K oncogenic fusions
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469173/